Aerie Pharmaceuticals, Inc. (AERI): Price and Financial Metrics
GET POWR RATINGS... FREE!
AERI POWR Grades
- Value is the dimension where AERI ranks best; there it ranks ahead of 78.01% of US stocks.
- AERI's strongest trending metric is Stability; it's been moving up over the last 198 days.
- AERI ranks lowest in Momentum; there it ranks in the 5th percentile.
AERI Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for AERI is 3.47 -- better than 87% of US stocks.
- AERI's price/sales ratio is 9.5; that's higher than the P/S ratio of 81.64% of US stocks.
- AERI's equity multiplier -- a measure of assets relative to shareholders'equity -- is greater than that of 78.17% of US stocks.
- Stocks that are quantitatively similar to AERI, based on their financial statements, market capitalization, and price volatility, are YEXT, CLGN, PAYS, MC, and DHIL.
- AERI's SEC filings can be seen here. And to visit Aerie Pharmaceuticals Inc's official web site, go to www.aeriepharma.com.
AERI Price Target
For more insight on analysts targets of AERI, see our AERI price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $27.25 | Average Broker Recommendation | 1.46 (Moderate Buy) |
AERI Stock Price Chart Interactive Chart >
AERI Price/Volume Stats
| Current price | $16.84 | 52-week high | $21.30 |
| Prev. close | $16.94 | 52-week low | $9.01 |
| Day low | $16.25 | Volume | 730,200 |
| Day high | $17.20 | Avg. volume | 643,328 |
| 50-day MA | $18.40 | Dividend yield | N/A |
| 200-day MA | $14.28 | Market Cap | 789.63M |
Aerie Pharmaceuticals, Inc. (AERI) Company Bio
Aerie Pharmaceuticals is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The company was founded in 2005 and is based in Irvine, California.
Latest AERI News From Around the Web
Below are the latest news stories about Aerie Pharmaceuticals Inc that investors may wish to consider to help them evaluate AERI as an investment opportunity.
Aerie Pharmaceuticals Completes Enrollment of its Phase 2b Clinical Trial of AR-15512 (TRPM8 Agonist) Ophthalmic Solution for the Treatment of Patients with Dry Eye DiseaseAerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced the completion of patient enrollment for COMET-1, a Phase 2b clinical trial of AR-15512 (TRPM8 Agonist) ("AR-15512") ophthalmic solution for the treatment of patients with dry eye disease. |
Aerie Pharmaceuticals Receives Marketing Authorisation of Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) in Great BritainAerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Roclanda® 50 micrograms/ml + 200 micrograms/ml Eye Drops, Solution (latanoprost + netarsudil) ("Roclanda®") has received marketing authorisation from the Medicines and Healthcare Products Regulatory Agency ("MHRA") in Great Britain. Roclanda® is indicated for the reduction of elevated intraocular pressure ("IOP") in adult patients with primary open-angle glaucoma or ocular hypertension for whom monotherapy with a prostaglandin or netarsudil provides insufficient IOP reduction (reference Great Britain... |
Aerie Pharmaceuticals (AERI) Investor Presentation - SlideshowThe following slide deck was published by Aerie Pharmaceuticals, Inc. in conjunction with this event.... |
Aerie Pharmaceuticals to Participate in the 20th Annual Needham Virtual Healthcare ConferenceAerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Vicente Anido, Jr., Ph.D., Chairman and Chief Executive Officer, will present in a fireside discussion at the 20th Annual Needham Virtual Healthcare Conference on Wednesday, April 14, 2021 at 12:45 p.m. Eastern Time. Dr. Anido will provide an Aerie overview and business update. |
Aerie Pharmaceuticals to Participate in the Oppenheimer 31st Annual Virtual Healthcare ConferenceDURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with open-angle glaucoma, ocular surface diseases and retinal diseases, today announced that Richard J. Rubino, Chief Financial Officer, will present in a fireside discussion at the Oppenheimer 31st Annual Virtual Healthcare Conference on Wednesday, March 17, 2021 at 8 |
AERI Price Returns
| 1-mo | -3.00% |
| 3-mo | -4.75% |
| 6-mo | 59.47% |
| 1-year | 7.47% |
| 3-year | -66.88% |
| 5-year | 25.30% |
| YTD | 24.65% |
| 2020 | -44.10% |
| 2019 | -33.05% |
| 2018 | -39.58% |
| 2017 | 57.86% |
| 2016 | 55.44% |
Continue Researching AERI
Want to see what other sources are saying about Aerie Pharmaceuticals Inc's financials and stock price? Try the links below:Aerie Pharmaceuticals Inc (AERI) Stock Price | Nasdaq
Aerie Pharmaceuticals Inc (AERI) Stock Quote, History and News - Yahoo Finance
Aerie Pharmaceuticals Inc (AERI) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...